Complementary value of digital pathology to ctDNA in risk stratification of stage III colon cancer patients receiving adjuvant chemotherapy

I.A. Franken¹, M.E. Bakker¹, S.G. Elias², M.M. Laclé¹, N. Stathonikos¹, C. Rubio-Alarcón³, M. Sausen⁴, M. Koopman¹, G.A. Meijer³, G.R. Vink^{1,5}, R.J.A. Fijneman³, A. Storsve⁶, S. De Raedt^{6,7}, K. Cyll⁷, O.J. Skrede⁷, H.A. Askautrud⁷, T.S. Hveem⁷, L.H. Saal⁷, T. Furuseth⁷, A. Kleppe⁷ J.M.L. Roodhart¹

1. University Medical Center Utrecht, The Netherlands; 2. Julius Centre for Health Sciences and Primary Care, The Netherlands; 3. The Netherlands Cancer Institute, The Netherlands; 4. Labcorp, USA; 5. Netherlands Comprehensive Cancer Organisation, The Netherlands; 6. DoMore Diagnostics, Norway; 7. Institute for Cancer Genetics and Informatics, Norway

which alone cures already ~50% of patients.

Patient selection



Analyses

Rubio-Alarcon AACR 2024; 2. Kleppe Lancet Oncol 2022; 3. Skrede & de Raedt, Lancet 2020.



PLCRC for the research infrastructure and clinical data; Labcorp Oncology for the ctDNA analysis; DoMore Diagnostics for the digital pathology biomarker.



PROVENC3 is co-funded by the PPP Allowance made available by Health~Holland (LSHM #19027) and the Dutch Cancer Society (KWF #11809); CAPAI is developed thanks to funding by Learning from Deep learning, The Norwegian Research Council (#334862) and Improving diagnosis by utilizing Big Data and software-driven automation of pathology, The Norwegian Research Council (#259204).